Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics Inc (NQ: IOVA )

8.320 +0.080 (+0.97%)
Streaming Delayed Price Updated: 10:02 AM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Iovance Biotherapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
2 Innovative Stocks That Could Deliver Outsize Returns
Via The Motley Fool
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More
Via The Motley Fool
A Peek at Iovance Biotherapeutics's Future Earnings
Via Benzinga
Why Iovance Biotherapeutics Stock Triumphed on Thursday
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout. 
Via The Motley Fool
Is Iovance Biotherapeutics Stock a Buy?
The biotech is making important breakthroughs, but is that enough? 
Via The Motley Fool
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow
This biotech's growth story is going to start moving faster, and soon. 
Via The Motley Fool
(IOVA) - Analyzing Iovance Biotherapeutics's Short Interest
Via Benzinga
Looking Into Iovance Biotherapeutics's Recent Short Interest
Via Benzinga
Iovance Biotherapeutics Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Via Benzinga
What the Options Market Tells Us About Iovance Biotherapeutics
Via Benzinga
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today
There's plenty of upside with this stock, but it might take a while to realize. 
Via The Motley Fool
AST SpaceMobile And Polestar Automotive Are Among Top 10 Best Performing Mid-Cap Stocks in August: Are The Others In Your Portfolio?
The top 10 mid-cap stocks in August: Polestar Automotive, Upstart, Lumen Technologies, GDS Holdings, Tempus AI, Clear Secure, Iovance Biotherapeutics, Evolent Health, Semtech Corp, AST SpaceMobile. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
This Is the Biggest Risk With Iovance Biotherapeutics Stock
Investors should brace for dilution. 
Via The Motley Fool
3 Monster Biotech Stocks to Buy Before 2025
These companies are nearly in the sweet spot of risk versus reward in biotech. 
Via The Motley Fool
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?
This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace. 
Via The Motley Fool
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock
It could demonstrate a few capabilities that no other biotech has as of yet. 
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Iovance Biotherapeutics Shares Are Soaring Today
The biopharma company is proving its recently approved cancer therapy is marketable. 
Via The Motley Fool
Why Is Iovance Bio (IOVA) Stock Up 18% Today?
Iovance Biotherapeutics stock is gaining as IOVA investors react to strong Q2 earnings beats and positive guidance for 2024 and 2025. 
Via InvestorPlace
Topics Earnings
Exposures Financial
Skin Cancer-Focused Iovance Biotherapeutics Reports Better-Than-Expected 2024, 2025 Outlook, Stock Surges
Iovance Biotherapeutics stock up 23.2% after issuing upbeat guidance for 2024 and 2025, beating Q2 earnings expectations. 
Via Benzinga
Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
Via Benzinga
IOVA Stock Earnings: Iovance Biotherapeutics Beats EPS, Beats Revenue for Q2 2024
IOVA stock results show that Iovance Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
10 Best Small and Mid-Cap Stocks to Consider Buying in August
A shift in market dynamics could favor these 10 growth stocks. 
Via The Motley Fool
Iovance Biotherapeutics Attracted a Downgrade. Is It Time to Sell?
Find out how concerned investors should be about setbacks for this company's revolutionary new cancer therapies. 
Via The Motley Fool
Why Iovance Biotherapeutics Stock Stumbled Today
One pundit warns of apparent manufacturing issues with the company's melanoma drug. 
Via The Motley Fool
Iovance Biotherapeutics Price Forecast Slashed By 40% On Mutated Uptake For Its Newly Approved Skin Cancer Cell Therapy
Piper Sandler downgraded Iovance Biotherapeutics due to a slow launch of Amtagvi (lifileucel), a skin cancer treatment. Despite patient demand, extended treatment timelines and low infusion rates led... 
Via Benzinga
Life May Soon Get Easier for (Some) Biotech Stocks. Here's Why.
The Federal Reserve's fight against inflation may soon yield financial benefits. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
ViaSat & AST SpaceMobile Are Among Top 6 Mid Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?
Top mid-cap stocks of the week: ASTS up 47.88%, GSHD up 39.86%, VSAT up 30.78%, VKTX up 29.86%, BEAM up 23.93%, CLDX up 19.72% 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.